716. *In vitro* and *In vivo* Nonclinical Efficacy of AR-501 (Gallium Citrate)

Jennifer Woo, BVSc, PhD[1]; Ken Hearne, BS[1]; Andy Kelson, PhD[1];
Luisa Yee, PhD[1]; Cecilia Espadas, PhD[1]; Vu L. Truong, PhD[2]; [1]Aridis Pharmaceuticals, San Jose, California; [2]Aridis Pharmaceuticals Ltd., San Jose, California

Session: 68. Novel Antimicrobials and Approaches Against Resistant Bugs
Thursday, October 3, 2019: 12:15 PM

Background. Gallium nitrate citrate exhibits strong antibacterial activity and was recently shown to be safe and efficacious when intravenously administered to cystic fibrosis patients in a Phase 2 clinical study conducted by the University of Washington. We are developing an inhaled formulation of gallium citrate (AR-501), which is being tested in a Phase 1/2a clinical study. The *in vitro* antimicrobial activities, drug resistance profile, activities in combination with selected antibiotics, and *in vivo* animal efficacy if the inhaled vs. IV formulation is being presented.

Methods. MIC tests were performed on strains using the CLSI susceptibility test standards. Resistance testing exposed bacteria to 20 cycles at ranges above and below the MIC level of the drug used.SPF mice (C57BL/6J, 7–9 weeks) were inoculated intranasally with *P. aeruginosa* under ketamine/xylazine anesthesia. Inhalation of AR-501 used an Aeroneb Solo nebulizer. Gallium levels were determined by elemental analysis using atomic absorption spectroscopy. CFU levels were measured by enumeration of bacterial colonies following serial dilution of tissue homogenates.

Results. *In vitro* efficacy: MIC testing demonstrates the efficacy of AR-501 against gram (−), gram (+) and several species of mycobacteria of clinical isolates and the comparative antibacterial response with antibiotics. Resistance testing showed that AR-501 exhibited lower propensity to develop resistance than the antibiotics tested. *In vivo* efficacy: AR-501 Inhalation also increased the median survival time compared with IV dosing in the murine model. Bacterial clearance was increased when Tobramycin and AR-501 are co-administered. Comparative analysis of AR-501 after IH route demonstrate increased gallium levels in BAL and reduced levels in the kidney in contrast to IV route.

Conclusion. *In vitro* studies demonstrate the susceptibility of gram (−), gram (+) and mycobacteria pathogens and the dose range of AR-501 compared with SOC antibiotics. *In vivo* studies confirm the therapeutic efficacy of AR-501 in bacterial pneumonia by IH delivery and demonstrate that bacterial clearance is enhanced when SOC antibiotics are used in combination with AR-501.


Figure 2. Differential distribution of gallium in tissues and BAL following inhalation or intravenous delivery.


Fig 2. Gallium levels were measured in serum, kidney and bronchial lavage samples over 24 hours after delivery by inhalation (A) or intravenous (B) routes. C57BL/6J mice (n=6 per group) were dosed with AR-501 and samples collected after 0.08, 0.5, 1, 6, and 24 hours post-treatment for gallium measurement.

Bacterial Levels in Murine Lung Tissues

Disclosures. All authors: No reported disclosures.

717. Lefamulin (LEF) vs. Moxifloxacin (MOX) in Patients With Community-Acquired Bacterial Pneumonia (CABP) at Risk for Poor Efficacy or Safety Outcomes: Pooled Subgroup Analyses From the Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 Phase 3 Noninferiority Clinical Trials

Jennifer Schranz, MD[1]; Lisa Goldberg, MS[1]; Anita F. Das, PhD[2];
Elizabeth Alexander, MD, MSc., FIDSA[1]; Gregory J. Moran, MD[3];
Christian Sandrock, MD[4]; Andrew F. Shorr, MD, MPH, MBA[5];
Steven P. Gelone, PharmD[1]; [1]Nabriva Therapeutics US, Inc., King of Prussia, Pennsylvania; [2]Das Consulting, Guerneville, California; [3]Olive View-UCLA Medical Center, Sylmar, California; [4]UC Davis School of Medicine, Sacramento, California; [5]Medstar Washington Hospital Center, Washington, DC

Session: 68. Novel Antimicrobials and Approaches Against Resistant Bugs
*Thursday, October 3, 2019: 12:15 PM*

Background. In the United States, CABP is the second most common cause of hospitalization and a leading cause of infectious death. Patients with chronic obstructive pulmonary disease (COPD)/asthma or diabetes are at risk for CABP and associated mortality. Similarly, patients with underlying cardiac or liver disease are at risk for potential cardiac or liver toxicities, respectively, associated with CABP antimicrobials, and patients aged ≥65 years are at risk for both efficacy/safety concerns. We report pooled efficacy/safety outcomes in at-risk subgroups from the LEAP 1 and 2 phase 3 trials.

Methods. In LEAP 1, patients with CABP (PORT III–V) received IV LEF 150 mg q12h for 5–7 days or MOX 400mg q24h for 7 days, with optional IV-to-oral switch (600 mg LEF q12h or 400 mg MOX q24h). In LEAP 2, patients with CABP (PORT II–IV) received oral LEF 600 mg q12h for 5 days or MOX 400 mg q24h for 7 days. Both studies assessed early clinical response (ECR; 96 ± 24 hours after first dose) in the intent-to-treat (ITT; all randomized patients) population (FDA primary endpoint) and investigator assessment of clinical response (IACR) at test-of-cure (TOC; 5–10 days after last dose) in the modified ITT (≥1 study drug dose) and clinically evaluable (met predefined evaluability criteria) populations (EMA coprimary endpoints). Pooled analyses used a 10% noninferiority margin. Safety was assessed in all randomized and treated patients.

Results. 1289 ITT patients were randomized to LEF (n = 646) or MOX (n = 643); of whom, 297 (23.0%) were aged 65–74 years and 220 (17.1%) were ≥75 years; 232 patients (18.0%) had COPD/asthma and 168 (13.0%) had diabetes mellitus (DM). At baseline, 501 patients (38.9%) had history of hypertension, 73 (5.7%) had history of arrhythmia, and 263 (20.4%) had transaminitis. The figure shows efficacy by age and in COPD/asthma and DM patients. Treatment-emergent adverse events, electrocardiogram assessments, and laboratory results in patients at risk for cardiac and hepatic safety concerns are shown in Tables 1 and 2.

Conclusion. In pooled analyses of LEAP 1 and 2, LEF efficacy was high and similar to MOX in patients at risk of efficacy concerns and LEF showed a safety profile similar to that of MOX in patients at risk of safety concerns. LEF is a promising new option for IV/oral monotherapy of CABP in patients at risk of poor outcomes due to CABP or to antimicrobial therapy for CABP.

Figure. ECR* Rates by Subgroup (ITT Population)

Table 1. Cardiac TEAEs and Postbaseline ECG Changes in Patients at Risk for Cardiac Safety Concerns

Patients with history of hypertension, n (%)	LEF (n=246)	MOX (n=252)
TEAEs in cardiac SOC*	8 (3.3)	8 (3.2)
TE-AESIs in QT prolongation category†	1 (0.4)	4 (1.6)
Patients with both baseline and postbaseline values of QTcF	(n=244)	(n=251)
Increase in QTcF	215 (88.1)	223 (88.8)
Increase >30 msec in QTcF	45 (18.4)	57 (22.7)
Increase >60 msec in QTcF	4 (1.6)	8 (3.2)
Value QTcF >480 msec	10 (4.1)	9 (3.6)
Value QTcF >500 msec	1 (0.4)	2 (0.8)
Baseline QTcF ≤480 msec and postbaseline QTcF >480 msec	9 (3.7)	7 (2.8)
Baseline QTcF ≤500 msec and postbaseline QTcF >500 msec	1 (0.4)	1 (0.4)
Patients with history of arrhythmia, n (%)	**LEF (n=42)**	**MOX (n=30)**
TEAEs in cardiac SOC‡	4 (9.5)	3 (10.0)
TE-AESIs in QT prolongation category†	2 (4.8)	1 (3.3)
Patients with both baseline and postbaseline values of QTcF	(n=42)	(n=30)
Increase in QTcF	36 (85.7)	22 (73.3)
Increase >30 msec in QTcF	10 (23.8)	8 (26.7)
Increase >60 msec in QTcF	1 (2.4)	3 (10.0)
Value QTcF >480 msec	2 (4.8)	3 (10.0)
Value QTcF >500 msec	0	1 (3.3)
Baseline QTcF ≤480 msec and postbaseline QTcF >480 msec	2 (4.8)	2 (6.7)
Baseline QTcF ≤ 500 msec and postbaseline QTcF >500 msec	0	0
Patients aged ≥65 y, n (%)	**LEF (n=267)**	**MOX (n=248)**
TEAEs in cardiac SOC§	3 (1.1)	3 (1.2)
Patients with both baseline and postbaseline values of QTcF	(n=266)	(n=247)
Increase in QTcF	234 (88.0)	218 (88.3)
Increase >30 msec in QTcF	52 (19.5)	49 (19.8)
Increase >60 msec in QTcF	4 (1.5)	7 (2.8)
Value QTcF >480 msec	11 (4.1)	14 (5.7)
Value QTcF >500 msec	1 (0.4)	6 (2.4)
Baseline QTcF ≤480 msec and postbaseline QTcF >480 msec	10 (3.8)	10 (4.0)
Baseline QTcF ≤500 msec and postbaseline QTcF >500 msec	1 (0.4)	4 (1.6)

ECG=electrocardiogram; LEF=lefamulin; MOX=moxifloxacin; QTcF=QT interval corrected according to Fridericia; SMQ=Standardized Medical Dictionary for Regulatory Activities query; SOC=system organ class; TEAE=treatment-emergent adverse event; TE-AESI=treatment-emergent adverse event of special interest.
*Specific preferred terms that occurred in >1 patient were myocardial infarction (n=2 LEF), acute myocardial infarction (n=2 MOX), and atrial fibrillation (n=3 MOX). All other cardiac TEAEs occurred in ≤1 patient per treatment group.
†QT prolongation category included broad SMQ search for "Torsades des Pointes/QT Prolongation."
‡Specific preferred terms that occurred in >1 patient were atrial fibrillation (n=2 LEF). All other cardiac TEAEs occurred in ≤1 patient per treatment group.
§All cardiac TEAEs occurred in ≤1 patient per treatment group.

Table 2. Hepatobiliary TEAEs and Postbaseline Liver Enzyme Changes in Patients at Risk for Hepatic Safety Concerns

Patients with baseline liver enzyme elevation (AST or ALT >ULN)	LEF (n=119)	MOX (n=144)
TEAEs in hepatobiliary SOC,* n (%)	4 (3.4)	3 (2.1)
TE-AESIs in liver safety,† n (%)	2 (1.7)	9 (6.3)
Any postbaseline value, n/N (%)		
ALT >3 ×ULN	2/36 (5.6)	5/34 (14.7)
ALT >5 ×ULN	1/36 (2.8)	1/34 (2.9)
ALT >10 ×ULN	0/36	0/34
AST >3 ×ULN	0/23	0/39
AST >5 ×ULN	0/23	0/39
AST >10 ×ULN	0/23	0/39
Total bilirubin value >2 ×ULN	1/102 (1.0)	1/124 (0.8)
ALT or AST >3 ×ULN and total bilirubin value >2 ×ULN	0/55	1/64 (1.6)
Patients aged ≥65 y	**LEF (n=267)**	**MOX (n=248)**
TEAEs in hepatobiliary SOC,* n (%)	2 (0.7)	1 (0.4)
Any postbaseline value, n/N (%)		
ALT >3 ×ULN	11/262 (4.2)	8/242 (3.3)
ALT >5 ×ULN	3/262 (1.1)	4/242 (1.7)
ALT >10 ×ULN	1/262 (0.4)	0/242
AST >3 ×ULN	6/262 (2.3)	4/242 (1.7)
AST >5 ×ULN	2/262 (0.8)	2/242 (0.8)
AST >10 ×ULN	1/262 (0.4)	0/242
Total bilirubin value >2 ×ULN	0/262	1/242 (0.4)
ALT or AST >3 ×ULN and total bilirubin value >2 ×ULN	0/262	1/242 (0.4)

ALT=alanine aminotransferase; AST=aspartate aminotransferase; LEF=lefamulin; MOX=moxifloxacin; SMQ=Standardized Medical Dictionary for Regulatory Activities query; SOC=system organ class; TEAE=treatment-emergent adverse event; TE-AESI=treatment-emergent adverse event of special interest; ULN=upper limit of normal.
*No hepatobiliary TEAE occurred in more than one patient per treatment group.
†TE-AESIs in the liver safety SMQ included broad searches for "liver related investigations, signs, symptoms" and "biliary related investigations, signs, symptoms."

Disclosures. **All authors:** No reported disclosures.

---

718. Activity of Ceftolozane–Tazobactam and Ceftazidime–Avibactam Against Clinical *P. aeruginosa* Isolates Collected in United States and Canada—SMART 2018

Sibylle Lob, PhD[1]; Krystyna Kazmierczak, PhD[1]; Janet Raddatz, PharmD[2]; Daryl DePestel, PharmD, BCPS-ID [2]; Katherine Young, MS[2]; Mary Motyl, PhD[2]; Daniel F. Sahm, PhD[1]; [1]IHMA, Inc., Schaumburg, Illinois; [2]Merck & Co, Inc, Kenilworth, New Jersey

Session: 68. Novel Antimicrobials and Approaches Against Resistant Bugs
Thursday, October 3, 2019: 12:15 PM

Background. Ceftolozane–tazobactam (C/T) is an antipseudomonal cephalosporin combined with a β-lactamase inhibitor. The combination was cleared by FDA and EMA and is approved in the United States and over 60 countries worldwide. Using clinical isolates collected in the United States and Canada as part of the global SMART surveillance program, we compared the activity of C/T and ceftazidime–avibactam (CAZ/AVI) against *P. aeruginosa* isolates and subsets nonsusceptible (NS) to selected antimicrobial agents.

Methods. In 2018, 31 clinical laboratories from United States and Canada collected up to 250 consecutive, aerobic or facultatively anaerobic, Gram-negative pathogens (GNP) from blood, intra-abdominal, urinary, and lower respiratory tract infections. A total of 6,178 GNP were collected, of which 1,138 (18.4%) were *P. aeruginosa*. MICs were determined using CLSI broth microdilution and interpreted with CLSI 2019 breakpoints.

Results. The MIC distributions of C/T and CAZ/AVI against 1,138 *P. aeruginosa* are shown below. The modal MIC value for C/T was ≥2 doubling dilutions lower than that for CAZ/AVI, and it was ≥3 dilutions lower than the C/T CLSI susceptible breakpoint, whereas the modal MIC value for CAZ/AVI was 2 dilutions lower than its susceptible breakpoint. Among all *P. aeruginosa* isolates, percentages of susceptibility were 96.0% (C/T), 93.8% (CAZ/AVI), 76.6% (CAZ and cefepime), 67.0% (imipenem [IMI]), 74.0% (meropenem [MEM]), 71.5% (piperacillin–tazobactam [TZP]), and 64.9% (aztreonam). Among subsets of nonsusceptible isolates, susceptibilities to C/T and CAZ/AVI were 83.5% and 74.4%, respectively (CAZ-NS subset, n = 266), 91.0% and 85.1% (IMI-NS, n = 376), 87.5% and 80.1% (MEM-NS, n = 296), 87.0% and 79.6% (TZP-NS, n = 324), and 72.4% and 57.8% among isolates nonsusceptible to all tested β-lactams (n = 116).

Conclusion. The activity of C/T exceeded that of CAZ/AVI and other tested comparators against a recent collection of clinical isolates of *P. aeruginosa*, including subsets of isolates nonsusceptible to other β-lactams. Susceptibilities to C/T were 6–14 percentage points higher than observed for CAZ/AVI among β-lactam-NS subsets. C/T promises to be an important treatment option for patients with antimicrobial-resistant *P. aeruginosa* infections.

Arrows indicate the modes of the respective MIC distributions. Dashed line represents the C/T CLSI susceptible breakpoint, dotted line the CAZ/AVI CLSI susceptible breakpoint

Disclosures. **All authors:** No reported disclosures.

---

719. Cefiderocol Retains Anti-Biofilm Activity in MDR Gram-Negative Pathogens

Christine A. Pybus, MS[1]; David E. Greenberg, MD[2]; [1]UT Southwestern Medical Center, Dallas, Texas; [2]UT Southwestern Medical Center, Dallas, Texas

Session: 68. Novel Antimicrobials and Approaches Against Resistant Bugs
Thursday, October 3, 2019: 12:15 PM

Background. Cefiderocol is a siderophore cephalosporin with potent antibacterial activity against a broad range of Gram-negative pathogens. Microorganisms forming biofilm, e.g., cUTI, utilize bacterial siderophores to access free iron. A siderophore antibiotic may have unique antimicrobial properties in the setting of biofilm. In this study, we compared antimicrobial activity of cefiderocol to comparator antibiotics in well-characterized multi-drug-resistant pathogens. We determined the activity of cefiderocol and comparator antibiotics in the biofilm setting.

Methods. Minimum inhibitory concentrations (MICs) in Mueller–Hinton II broth (MHII) and iron-depleted cation-adjusted MHII (ID-CAMHB) were determined for cefiderocol and seven comparator antibiotics in multidrug-resistant isolates of *P. aeruginosa*, *Burkholderia cepacia* complex (Bcc), *Klebsiella pneumoniae*, *Escherichia coli*, and *Acinetobacter baumannii*. MBEC (minimum biofilm eradication concentration) assays were used to test cefiderocol's activity in biofilms formed on pegs. Total biofilm biomass and viable cell number were measured.

Results. The MIC_{90} of cefiderocol ranged from 0.125 μg/mL (Bcc) to 1 μg/mL (*P. aeruginosa*) in ID-CAMHB. MIC_{90} values were consistently lower for cefiderocol in all strains tested compared with other agents (ceftolozane-tazobactam, ceftazidime–avibactam, ceftazidime, pipercallin-tazobactam, imipenem, tobramycin, clarithromycin). Twenty-four hour *P. aeruginosa* biofilms (strains ATCC 9027, MB640, MB771, MB580A, MB730) were treated every 12 hours with 4 μg/mL of cefiderocol or comparator antibiotics. Cefiderocol treatment displayed a superior reduction in biofilm based on colony counts (>90%; $P < 0.0001$ vs. untreated control) compared with comparator drugs (50 to 80% reduction). Crystal violet staining revealed a dose-dependent response of cefiderocol in the reduction of biofilm. Reduction of biofilm was not significantly altered by the growth media that was used; however, *P. aeruginosa* strains form more biofilm in MHII.

Conclusion. Cefiderocol effectively reduces biofilm in multidrug-resistant strains of *P. aeruginosa* and is a potent inhibitor of planktonic growth across a range of Gram-negative medically important pathogens.

Disclosures. **All authors:** No reported disclosures.